Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Kalra

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Blood Advances|October 19, 2020
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19Mohammed Osman, Rehan M Faridi, Wendy Sligl, et al.
Transplantation and Cellular Therapy|October 4, 2021
Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell TransplantationMegan Kinzel, Michelle Dowhan, Amit Kalra, et al.
Cytotherapy|January 1, 2020
High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern eraChristopher Evernden, Michelle Dowhan, Rosy Dabas, et al.
Cytotherapy|September 3, 2022
Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host diseaseRutvij A Khanolkar, Gaurav Tripathi, Poonam Dharmani-Khan, et al.
Bone Marrow Transplantation|April 2, 2020
Curability and transferability of atopy with allogeneic hematopoietic cell transplantationSarah Whiteside, Alex Chin, Gaurav Tripathi, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Blood Advances|October 19, 2020
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19Mohammed Osman, Rehan M Faridi, Wendy Sligl, et al.
Transplantation and Cellular Therapy|October 4, 2021
Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell TransplantationMegan Kinzel, Michelle Dowhan, Amit Kalra, et al.
Cytotherapy|January 1, 2020
High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern eraChristopher Evernden, Michelle Dowhan, Rosy Dabas, et al.
Cytotherapy|September 3, 2022
Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host diseaseRutvij A Khanolkar, Gaurav Tripathi, Poonam Dharmani-Khan, et al.
Bone Marrow Transplantation|April 2, 2020
Curability and transferability of atopy with allogeneic hematopoietic cell transplantationSarah Whiteside, Alex Chin, Gaurav Tripathi, et al.
Pageof 4